Virulence Mechanisms of Viral Bcl-2 Homologs

病毒 Bcl-2 同源物的毒力机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): DNA viruses are responsible for extensive morbidity and mortality on a worldwide basis. Viral homologs of anti-apoptotic Bcl-2 family proteins are encoded in the genomes of several classes of DNA viruses. In Vaccinia Virus (VV), a poxvirus-family member that has served as a paradigm for investigations of many aspects of host-pathogen interactions, at least two viral Bcl-2 genes have been identified, F1L and N1L. Neither F1L nor N1L is required for VV infection or replication, but both of these genes make strong contributions to virulence in vivo. Thus, these viral Bcl-2 (vBcl-2) homologs are critically important for in vivo viral pathogenicity of VV. While the anti-apoptotic activity of F1L and N1L is an obvious candidate for explaining their contribution to viral virulence, we have discovered that F1L and N1L have additional functions that include binding to and suppressing the pro-inflammatory actions of NLR-family proteins, important mediators of innate immunity. Viral Bcl-2 proteins are also known to bind Beclin and suppress autophagy, recently recognized as a host defense mechanism against pathogens. We hypothesize the vBcl-2 homologs are multifunctional proteins that utilize 3 discrete mechanisms to thwart host defense mechanisms: (a) suppression of apoptosis; (b) inhibition of autophagy; and (c) interference with NLR-mediated innate immune responses. The hypothesis that we will test is that neutralization by vBcl-2 proteins of each of these 3 classes of host cell targets significantly contributes to virulence. Specifically, we will: (1) Produce site-specific mutations in F1L and N1L that selectively abolish their ability to interact with (a) pro-apoptotic Bcl-2 family proteins [apoptosis]; (b) NLRs [inflammation]; and (c) Beclin [autophagy]; (2) Test the effects of the engineered vBcl-2 proteins on apoptosis, inflammation, and autophagy in cultured cells; (3) Produce recombinant vaccinia viruses with knock-in of F1L and N1L mutants; and (4) Compare the virulence of these recombinant vaccinia viruses in mice. By using VV as a model system, our results will lay a foundation for understanding the role of viral Bcl-2 homologs in viral pathogenicity, thus serving as a paradigm for other DNA viruses that contain vBcl-2 genes and that cause debilitating human diseases. Also, by learning how viruses interfere with apoptosis, autophagy, and inflammation, the information generated may reveal novel strategies for mimicking aspects of vBcl-2 function in therapeutically useful ways for addressing disorders in which excessive apoptosis, autophagy, and inflammation play central roles.
描述(由申请人提供):DNA病毒在世界范围内造成广泛的发病率和死亡率。抗凋亡Bcl-2家族蛋白的病毒同源物被编码在几种DNA病毒的基因组中。牛痘病毒(VV)是痘病毒家族的一员,已成为研究宿主-病原体相互作用许多方面的范例,至少已鉴定出两个病毒Bcl-2基因,F1L和N1L。VV感染或复制都不需要F1L和N1L,但这两个基因都对体内毒力有很强的贡献。因此,这些病毒Bcl-2 (vBcl-2)同源物对VV的体内病毒致病性至关重要。虽然F1L和N1L的抗凋亡活性是解释它们对病毒毒力贡献的一个明显候选,但我们发现F1L和N1L具有其他功能,包括结合和抑制nlr家族蛋白的促炎作用,nlr家族蛋白是先天免疫的重要介质。病毒Bcl-2蛋白也被认为结合Beclin并抑制自噬,最近被认为是宿主对抗病原体的一种防御机制。我们假设vBcl-2同源物是多功能蛋白,利用3种不同的机制来破坏宿主防御机制:(a)抑制细胞凋亡;(b)抑制自噬;(c)干扰nlr介导的先天免疫反应。我们将测试的假设是,这三种宿主细胞靶点的vBcl-2蛋白的中和作用显著地促进了毒力。具体来说,我们将:(1)在F1L和N1L中产生位点特异性突变,选择性地破坏它们与(a)促凋亡的Bcl-2家族蛋白相互作用的能力[凋亡];(b) NLRs[炎症];(c) Beclin[自噬];(2)检测工程化vBcl-2蛋白对体外培养细胞凋亡、炎症和自噬的影响;(3)制备敲入F1L和N1L突变体的重组痘苗病毒;(4)比较这些重组痘苗病毒在小鼠体内的毒力。通过使用VV作为模型系统,我们的研究结果将为理解病毒Bcl-2同源物在病毒致病性中的作用奠定基础,从而为含有vcl -2基因的其他DNA病毒提供范例,并导致使人衰弱的疾病。此外,通过了解病毒如何干扰细胞凋亡、自噬和炎症,所产生的信息可能揭示模仿vBcl-2功能方面的新策略,以治疗有用的方式解决过度细胞凋亡、自噬和炎症起核心作用的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHU-ICHI MATSUZAWA其他文献

SHU-ICHI MATSUZAWA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHU-ICHI MATSUZAWA', 18)}}的其他基金

Virulence Mechanisms of Viral Bcl-2 Homologs
病毒 Bcl-2 同源物的毒力机制
  • 批准号:
    8389625
  • 财政年份:
    2010
  • 资助金额:
    $ 48.75万
  • 项目类别:
Virulence Mechanisms of Viral Bcl-2 Homologs
病毒 Bcl-2 同源物的毒力机制
  • 批准号:
    8766539
  • 财政年份:
    2010
  • 资助金额:
    $ 48.75万
  • 项目类别:
STRUCTURAL ANALYSIS OF PROTEIN COMPLEXES IN E3 LIGASE COMPLEX ASSEMBLY
E3 连接酶复合物组装中蛋白质复合物的结构分析
  • 批准号:
    7955253
  • 财政年份:
    2009
  • 资助金额:
    $ 48.75万
  • 项目类别:
STRUCTURAL ANALYSIS OF PROTEIN COMPLEXES IN E3 LIGASE COMPLEX ASSEMBLY
E3 连接酶复合物组装中蛋白质复合物的结构分析
  • 批准号:
    7722359
  • 财政年份:
    2008
  • 资助金额:
    $ 48.75万
  • 项目类别:
STRUCTURAL ANALYSIS OF PROTEIN COMPLEXES IN E3 LIGASE COMPLEX ASSEMBLY
E3 连接酶复合物组装中蛋白质复合物的结构分析
  • 批准号:
    7601706
  • 财政年份:
    2007
  • 资助金额:
    $ 48.75万
  • 项目类别:
STRUCTURAL ANALYSIS OF PROTEIN COMPLEXES IN E3 LIGASE COMPLEX ASSEMBLY
E3 连接酶复合物组装中蛋白质复合物的结构分析
  • 批准号:
    7358722
  • 财政年份:
    2006
  • 资助金额:
    $ 48.75万
  • 项目类别:
Novel Pathway Connecting p53 to beta-Catenin degradation
连接 p53 与 β-Catenin 降解的新途径
  • 批准号:
    6899342
  • 财政年份:
    2004
  • 资助金额:
    $ 48.75万
  • 项目类别:
Novel Pathway Connecting p53 to beta-Catenin degradation
连接 p53 与 β-Catenin 降解的新途径
  • 批准号:
    6764813
  • 财政年份:
    2004
  • 资助金额:
    $ 48.75万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 48.75万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 48.75万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 48.75万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 48.75万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 48.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了